Augmentation of mouse natural killer (NK) activity by GM-1/p, a processed form of monosialoganglioside GM-1

Anna Giuffrida, Maria Cristina Galli, Angela Gismondi, Giorgio Santoni, Mario Piccoli, Giovanni Cavallo, Ezio Tubaro, Luigi Frati, Angela Santoni

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We describe the immunomodulatory activity of GM-1/P a processed form of GM-1 (monosialoganglioside) extracted from ox brain, purified and physically modified. We examined the effect of in vivo and in vitro treatment of GM-1/P on natural (NK) activity and its ability to induce the production of interleukin-2 (IL-2) in the mouse. In vivo treatment with GM-1/P (1 mg/Kg, i.v., day-1) resulted in a marked increase and in a change of distribution of NK activity, which was associated with lower density Percoll fractions. Marked increase was already observed at 18 hrs and then declined by day 4. In vitro treatment with GM-1/P (2ug/ml) enhanced NK activity of B6 spleen cells, already after 6 hours of incubation, remaining at plateau levels within 18 hours. A role of IL-2 in this enhancement was suggested by the ability of an anti-IL-2 rabbit antiserum to abolish in vitro increased cytotoxicity. the presence of IL-2 in the supernatants of splenocytes from GM-1/P (lmg/Kg, i.v., day-1) treated mice stimulated with Con A or Con A plus TPA for 48 hrs was evaluated by proliferation of an IL-2 dependent CTLL cell line. GM-1/P by itself was unable to stimulate IL-2 production; however it markedly increased IL-2 production induced by Con A or Con A plus TPA.

Original languageEnglish
Pages (from-to)545-563
Number of pages19
JournalImmunopharmacology and Immunotoxicology
Volume12
Issue number4
DOIs
Publication statusPublished - 1990

Fingerprint

Interleukin-2
Cytotoxicity
sialogangliosides
Immune Sera
Brain
Spleen
Cells
Rabbits
Cell Line
In Vitro Techniques

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology
  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Giuffrida, A., Galli, M. C., Gismondi, A., Santoni, G., Piccoli, M., Cavallo, G., ... Santoni, A. (1990). Augmentation of mouse natural killer (NK) activity by GM-1/p, a processed form of monosialoganglioside GM-1. Immunopharmacology and Immunotoxicology, 12(4), 545-563. https://doi.org/10.3109/08923979009019676

Augmentation of mouse natural killer (NK) activity by GM-1/p, a processed form of monosialoganglioside GM-1. / Giuffrida, Anna; Galli, Maria Cristina; Gismondi, Angela; Santoni, Giorgio; Piccoli, Mario; Cavallo, Giovanni; Tubaro, Ezio; Frati, Luigi; Santoni, Angela.

In: Immunopharmacology and Immunotoxicology, Vol. 12, No. 4, 1990, p. 545-563.

Research output: Contribution to journalArticle

Giuffrida, A, Galli, MC, Gismondi, A, Santoni, G, Piccoli, M, Cavallo, G, Tubaro, E, Frati, L & Santoni, A 1990, 'Augmentation of mouse natural killer (NK) activity by GM-1/p, a processed form of monosialoganglioside GM-1', Immunopharmacology and Immunotoxicology, vol. 12, no. 4, pp. 545-563. https://doi.org/10.3109/08923979009019676
Giuffrida, Anna ; Galli, Maria Cristina ; Gismondi, Angela ; Santoni, Giorgio ; Piccoli, Mario ; Cavallo, Giovanni ; Tubaro, Ezio ; Frati, Luigi ; Santoni, Angela. / Augmentation of mouse natural killer (NK) activity by GM-1/p, a processed form of monosialoganglioside GM-1. In: Immunopharmacology and Immunotoxicology. 1990 ; Vol. 12, No. 4. pp. 545-563.
@article{a353d9f14e9b4532b9130e35ab35c672,
title = "Augmentation of mouse natural killer (NK) activity by GM-1/p, a processed form of monosialoganglioside GM-1",
abstract = "We describe the immunomodulatory activity of GM-1/P a processed form of GM-1 (monosialoganglioside) extracted from ox brain, purified and physically modified. We examined the effect of in vivo and in vitro treatment of GM-1/P on natural (NK) activity and its ability to induce the production of interleukin-2 (IL-2) in the mouse. In vivo treatment with GM-1/P (1 mg/Kg, i.v., day-1) resulted in a marked increase and in a change of distribution of NK activity, which was associated with lower density Percoll fractions. Marked increase was already observed at 18 hrs and then declined by day 4. In vitro treatment with GM-1/P (2ug/ml) enhanced NK activity of B6 spleen cells, already after 6 hours of incubation, remaining at plateau levels within 18 hours. A role of IL-2 in this enhancement was suggested by the ability of an anti-IL-2 rabbit antiserum to abolish in vitro increased cytotoxicity. the presence of IL-2 in the supernatants of splenocytes from GM-1/P (lmg/Kg, i.v., day-1) treated mice stimulated with Con A or Con A plus TPA for 48 hrs was evaluated by proliferation of an IL-2 dependent CTLL cell line. GM-1/P by itself was unable to stimulate IL-2 production; however it markedly increased IL-2 production induced by Con A or Con A plus TPA.",
author = "Anna Giuffrida and Galli, {Maria Cristina} and Angela Gismondi and Giorgio Santoni and Mario Piccoli and Giovanni Cavallo and Ezio Tubaro and Luigi Frati and Angela Santoni",
year = "1990",
doi = "10.3109/08923979009019676",
language = "English",
volume = "12",
pages = "545--563",
journal = "Immunopharmacology and Immunotoxicology",
issn = "0892-3973",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Augmentation of mouse natural killer (NK) activity by GM-1/p, a processed form of monosialoganglioside GM-1

AU - Giuffrida, Anna

AU - Galli, Maria Cristina

AU - Gismondi, Angela

AU - Santoni, Giorgio

AU - Piccoli, Mario

AU - Cavallo, Giovanni

AU - Tubaro, Ezio

AU - Frati, Luigi

AU - Santoni, Angela

PY - 1990

Y1 - 1990

N2 - We describe the immunomodulatory activity of GM-1/P a processed form of GM-1 (monosialoganglioside) extracted from ox brain, purified and physically modified. We examined the effect of in vivo and in vitro treatment of GM-1/P on natural (NK) activity and its ability to induce the production of interleukin-2 (IL-2) in the mouse. In vivo treatment with GM-1/P (1 mg/Kg, i.v., day-1) resulted in a marked increase and in a change of distribution of NK activity, which was associated with lower density Percoll fractions. Marked increase was already observed at 18 hrs and then declined by day 4. In vitro treatment with GM-1/P (2ug/ml) enhanced NK activity of B6 spleen cells, already after 6 hours of incubation, remaining at plateau levels within 18 hours. A role of IL-2 in this enhancement was suggested by the ability of an anti-IL-2 rabbit antiserum to abolish in vitro increased cytotoxicity. the presence of IL-2 in the supernatants of splenocytes from GM-1/P (lmg/Kg, i.v., day-1) treated mice stimulated with Con A or Con A plus TPA for 48 hrs was evaluated by proliferation of an IL-2 dependent CTLL cell line. GM-1/P by itself was unable to stimulate IL-2 production; however it markedly increased IL-2 production induced by Con A or Con A plus TPA.

AB - We describe the immunomodulatory activity of GM-1/P a processed form of GM-1 (monosialoganglioside) extracted from ox brain, purified and physically modified. We examined the effect of in vivo and in vitro treatment of GM-1/P on natural (NK) activity and its ability to induce the production of interleukin-2 (IL-2) in the mouse. In vivo treatment with GM-1/P (1 mg/Kg, i.v., day-1) resulted in a marked increase and in a change of distribution of NK activity, which was associated with lower density Percoll fractions. Marked increase was already observed at 18 hrs and then declined by day 4. In vitro treatment with GM-1/P (2ug/ml) enhanced NK activity of B6 spleen cells, already after 6 hours of incubation, remaining at plateau levels within 18 hours. A role of IL-2 in this enhancement was suggested by the ability of an anti-IL-2 rabbit antiserum to abolish in vitro increased cytotoxicity. the presence of IL-2 in the supernatants of splenocytes from GM-1/P (lmg/Kg, i.v., day-1) treated mice stimulated with Con A or Con A plus TPA for 48 hrs was evaluated by proliferation of an IL-2 dependent CTLL cell line. GM-1/P by itself was unable to stimulate IL-2 production; however it markedly increased IL-2 production induced by Con A or Con A plus TPA.

UR - http://www.scopus.com/inward/record.url?scp=0025606818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025606818&partnerID=8YFLogxK

U2 - 10.3109/08923979009019676

DO - 10.3109/08923979009019676

M3 - Article

C2 - 2092039

AN - SCOPUS:0025606818

VL - 12

SP - 545

EP - 563

JO - Immunopharmacology and Immunotoxicology

JF - Immunopharmacology and Immunotoxicology

SN - 0892-3973

IS - 4

ER -